QuickLinks
-- Click here to rapidly navigate through this document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE TO
(RULE 14D-100)
Tender Offer Statement Under Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934
CYNOSURE, INC.
(Name of Subject Company)
MINUTEMAN MERGER SUB, INC.
(Offeror)
HOLOGIC, INC.
(Names of Filing Persons)
CLASS A COMMON STOCK, $0.001 PAR VALUE
(Title of Class of Securities)
232577205
(CUSIP Number of Class of Securities)
John M. Griffin, Esq.
General Counsel
250 Campus Drive
Marlborough, MA 01752
United States
(508) 263-2900
(Name, address and telephone number of person authorized to receive notices and communications on behalf of filing persons)
with copies to:
Adam O. Emmerich, Esq.
Benjamin M. Roth, Esq.
Wachtell, Lipton, Rosen & Katz
51 West 52nd Street
New York, NY 10019
(212) 403-1000
CALCULATION OF FILING FEE
|
|
|
|
Transaction Valuation*
|
|
Amount of Filing Fee**
|
|
$1,651,380,639.80
|
|
$191,395.02
|
|
-
*
-
Estimated
for purposes of calculating the filing fee only. The transaction valuation was calculated by adding the sum of (i) 23,914,023 shares of Class A
Common Stock, par value $0.001 per share (the "Shares"), of Cynosure, Inc. ("Cynosure") outstanding multiplied by the offer price of $66.00 per share, (ii) 370,993 Shares subject to
unvested restricted stock units multiplied by the offer price of $66.00 per share, (iii) 268,377 Shares subject to unvested performance stock units (assuming applicable performance criteria
were deemed satisfied at maximum performance) multiplied by the offer price of $66.00 per share and (iv) 776,660 Shares issuable pursuant to outstanding options with an exercise price less than
the offer price of $66.00 per share, multiplied by $39.73, which is the offer price of $66.00 per share minus the weighted average exercise price for such options of $26.27 per share. The calculation
of the filing fee is based on information provided by Cynosure as of February 16, 2017.
-
**
-
The
filing fee was calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory No. 1 for Fiscal
Year 2017, issued August 31, 2016, by multiplying the Transaction Valuation by 0.00011590.
-
o
-
Check
the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which
the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
|
|
|
|
|
|
Amount Previously Paid:
|
|
N/A
|
|
Filing Party:
|
|
N/A
|
Form or Registration No.:
|
|
N/A
|
|
Date Filed:
|
|
N/A
|
-
o
-
Check
the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
This
Tender Offer Statement on Schedule TO (this "Schedule TO") relates to the tender offer by Minuteman Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly
owned direct subsidiary of Hologic, Inc., a Delaware corporation ("Parent"), for all of the outstanding shares of Class A Common Stock, par value $0.001 per share ("Shares"), of
Cynosure, Inc., a Delaware corporation ("Cynosure"), at a price of $66.00 per share, net to the seller in cash, without interest thereon and less any applicable withholding taxes, upon the
terms and conditions set forth in the offer to purchase dated February 22, 2017 (the "Offer to Purchase"), a copy of which is attached as Exhibit (a)(1)(A), and in the related letter of
transmittal (the "Letter of Transmittal"), a copy of which is attached as Exhibit (a)(1)(B), which, as each may be amended or supplemented from time to time, collectively constitute the
"Offer."
All
the information set forth in the Offer to Purchase, including Schedule I thereto, is incorporated by reference herein in response to Items 1 through 9 and
Item 11 of this Schedule TO, and is supplemented by the information specifically provided in this Schedule TO.
Item 1.
Summary Term Sheet.
Regulation M-A Item 1001
The information set forth in the Offer to Purchase under the caption SUMMARY TERM SHEET is incorporated herein by reference.
Item 2.
Subject Company Information.
Regulation M-A Item 1002
(a)
Name and Address.
The name, address, and telephone number of the subject company's principal executive
offices are as follows:
Cynosure, Inc.
5 Carlisle Road
Westford, Massachusetts 01886
(978) 256-4200
(b)-(c)
Securities; Trading Market and Price.
The information set forth in the Offer to Purchase under the
following captions is incorporated herein by reference:
INTRODUCTION
THE
TENDER OFFERSection 6 ("Price Range of Shares; Dividends")
Item 3.
Identity and Background of Filing Person.
Regulation M-A Item 1003
(a)-(c)
Name and Address; Business and Background of Entities; and Business and Background of Natural
Persons.
The information set forth in the Offer to Purchase under the following captions is incorporated herein by reference:
SUMMARY
TERM SHEET
THE
TENDER OFFERSection 8 ("Certain Information Concerning Parent and Purchaser")
SCHEDULE
IInformation Relating to Parent and Purchaser
2
Item 4.
Terms of the Transaction.
Regulation M-A Item 1004
(a)
Material Terms.
The information set forth in the Offer to Purchase is incorporated herein by reference.
Item 5.
Past Contacts, Transactions, Negotiations and Agreements.
Regulation M-A Item 1005
(a)
Transactions.
The information set forth in the Offer to Purchase under the following captions is
incorporated herein by reference:
SUMMARY
TERM SHEET
THE
TENDER OFFERSection 10 ("Background of the Offer; Past Contacts or Negotiations with Cynosure")
(b)
Significant Corporate Events.
The information set forth in the Offer to Purchase under the following
captions is incorporated herein by reference:
SUMMARY
TERM SHEET
THE
TENDER OFFERSection 10 ("Background of the Offer; Past Contacts or Negotiations with Cynosure")
THE
TENDER OFFERSection 11 ("The Merger Agreement; Other Agreements")
THE
TENDER OFFERSection 12 ("Purpose of the Offer; Plans for Cynosure")
Item 6.
Purposes of the Transaction and Plans or Proposals.
Regulation M-A Item 1006
(a)
Purposes.
The information set forth in the Offer to Purchase under the following caption is incorporated
herein by reference:
THE
TENDER OFFERSection 12 ("Purpose of the Offer; Plans for Cynosure")
(c)
(1)-(7)
Plans
. The information set forth in the Offer to
Purchase under the following captions is incorporated herein by reference:
SUMMARY
TERM SHEET
THE
TENDER OFFERSection 9 ("Source and Amount of Funds")
THE
TENDER OFFERSection 10 ("Background of the Offer; Past Contacts or Negotiations with Cynosure")
THE
TENDER OFFERSection 11 ("The Merger Agreement; Other Agreements")
THE
TENDER OFFERSection 12 ("Purpose of the Offer; Plans for Cynosure")
THE
TENDER OFFERSection 13 ("Certain Effects of the Offer")
THE
TENDER OFFERSection 14 ("Dividends and Distributions")
3
Item 7.
Source and Amount of Funds or Other Consideration.
Regulation M-A Item 1007
(a)
Source of Funds.
The information set forth in the Offer to Purchase under the following captions is
incorporated herein by reference:
SUMMARY
TERM SHEET
THE
TENDER OFFERSection 9 ("Source and Amount of Funds")
THE
TENDER OFFERSection 10 ("Background of the Offer; Past Contacts or Negotiations with Cynosure")
(b)
Conditions.
The information set forth in the Offer to Purchase under the following captions is incorporated
herein by reference:
SUMMARY
TERM SHEET
THE
TENDER OFFERSection 9 ("Source and Amount of Funds")
THE
TENDER OFFERSection 10 ("Background of the Offer; Past Contacts or Negotiations with Cynosure")
THE
TENDER OFFERSection 11 ("The Merger Agreement; Other Agreements")
THE
TENDER OFFERSection 12 ("Purpose of the Offer; Plans for Cynosure")
THE
TENDER OFFERSection 15 ("Conditions of the Offer")
(d)
Borrowed Funds.
None.
Item 8.
Interest in Securities of the Subject Company.
Regulation M-A Item 1008
(a)
Securities Ownership.
The information set forth in the Offer to Purchase under the following captions is
incorporated herein by reference:
THE
TENDER OFFERSection 8 ("Certain Information Concerning Parent and Purchaser")
THE
TENDER OFFERSection 12 ("Purpose of the Offer; Plans for Cynosure")
SCHEDULE
IInformation Relating to Parent and Purchaser
(b)
Securities Transactions.
None.
Item 9.
Persons/Assets Retained, Employed, Compensated or Used.
Regulation M-A Item 1009
(a)
Solicitations or Recommendations.
The information set forth in the Offer to Purchase under the following
captions is incorporated herein by reference:
SUMMARY
TERM SHEET
THE
TENDER OFFERSection 3 ("Procedures for Accepting the Offer and Tendering Shares")
THE
TENDER OFFERSection 10 ("Background of the Offer; Past Contacts or Negotiations with Cynosure")
THE
TENDER OFFERSection 18 ("Fees and Expenses")
4
Item 10.
Financial Statements.
Regulation M-A Item 1010
(a)
Financial Information.
Not Applicable.
(b)
Pro Forma Information.
Not Applicable.
Item 11.
Additional Information.
Regulation M-A Item 1011
(a)
Agreements, Regulatory Requirements and Legal Proceedings.
The information set forth in the Offer to
Purchase under the following captions is incorporated herein by reference:
SUMMARY
TERM SHEET
THE
TENDER OFFERSection 10 ("Background of the Offer; Past Contacts or Negotiations with Cynosure")
THE
TENDER OFFERSection 11 ("The Merger Agreement; Other Agreements")
THE
TENDER OFFERSection 12 ("Purpose of the Offer; Plans for Cynosure")
THE
TENDER OFFERSection 13 ("Certain Effects of the Offer")
THE
TENDER OFFERSection 15 ("Conditions of the Offer")
THE
TENDER OFFERSection 16 ("Certain Legal Matters; Regulatory Approvals")
(c)
Other Material Information.
The information set forth in the Offer to Purchase and the Letter of Transmittal
is incorporated herein by reference.
Item 12.
Exhibits.
Regulation M-A Item 1016
|
|
|
Exhibit No.
|
|
Description
|
(a)(1)(A)
|
|
Offer to Purchase, dated February 22, 2017.
|
(a)(1)(B)
|
|
Letter of Transmittal.
|
(a)(1)(C)
|
|
Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
|
(a)(1)(D)
|
|
Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
|
(a)(1)(E)
|
|
Joint Press Release issued by Hologic, Inc. and Cynosure, Inc. on February 14, 2017 (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Hologic, Inc.
with the Securities and Exchange Commission on February 14, 2017).
|
(a)(1)(F)
|
|
Presentation of Hologic, Inc.Acquisition of Cynosure, dated February 14, 2017 (incorporated by reference to Exhibit 99.2 to the Current Report on Form 8-K filed by Hologic, Inc. with the
Securities and Exchange Commission on February 14, 2017).
|
(a)(1)(G)
|
|
Transcript of Investor Call dated February 14, 2017 (incorporated by reference to Exhibit 99.3 to the Current Report on Form 8-K filed by Hologic, Inc. with the Securities and Exchange Commission
on February 14, 2017).
|
(a)(1)(H)
|
|
Summary Advertisement as published in
The New York Times
on February 22, 2017.
|
(b)
|
|
None.
|
5
|
|
|
Exhibit No.
|
|
Description
|
(d)(1)
|
|
Agreement and Plan of Merger, dated as of February 14, 2017, by and among Cynosure, Inc., Minuteman Merger Sub, Inc. and Hologic, Inc. (incorporated by reference to Exhibit 2.1 to the Current
Report on Form 8-K filed by Hologic, Inc. with the Securities and Exchange Commission on February 14, 2017).
|
(g)
|
|
None.
|
(h)
|
|
None.
|
Item 13.
Information Required by Schedule 13E-3.
Not applicable.
6
SIGNATURES
After due inquiry and to the best of their knowledge and belief, each of the undersigned certifies that the information set forth in this
statement is true, complete and correct.
Dated:
February 22, 2017
|
|
|
|
|
|
|
MINUTEMAN MERGER SUB, INC.
|
|
|
By:
|
|
/s/ JOHN M. GRIFFIN
|
|
|
|
|
Name:
|
|
John M. Griffin
|
|
|
|
|
Title:
|
|
President
|
|
|
HOLOGIC, INC.
|
|
|
By:
|
|
/s/ JOHN M. GRIFFIN
|
|
|
|
|
Name:
|
|
John M. Griffin
|
|
|
|
|
Title:
|
|
General Counsel
|
|
|
7
EXHIBIT INDEX
|
|
|
Exhibit No.
|
|
Description
|
(a)(1)(A)
|
|
Offer to Purchase, dated February 22, 2017.
|
(a)(1)(B)
|
|
Letter of Transmittal.
|
(a)(1)(C)
|
|
Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
|
(a)(1)(D)
|
|
Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
|
(a)(1)(E)
|
|
Joint Press Release issued by Hologic, Inc. and Cynosure, Inc. on February 14, 2017 (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Hologic, Inc.
with the Securities and Exchange Commission on February 14, 2017).
|
(a)(1)(F)
|
|
Presentation of Hologic, Inc.Acquisition of Cynosure, dated February 14, 2017 (incorporated by reference to Exhibit 99.2 to the Current Report on Form 8-K filed by Hologic, Inc. with the
Securities and Exchange Commission on February 14, 2017).
|
(a)(1)(G)
|
|
Transcript of Investor Call dated February 14, 2017 (incorporated by reference to Exhibit 99.3 to the Current Report on Form 8-K filed by Hologic, Inc. with the Securities and Exchange Commission
on February 14, 2017).
|
(a)(1)(H)
|
|
Summary Advertisement as published in
The New York Times
on February 22, 2017.
|
(b)
|
|
None.
|
(d)(1)
|
|
Agreement and Plan of Merger, dated as of February 14, 2017, by and among Cynosure, Inc., Minuteman Merger Sub, Inc. and Hologic, Inc. (incorporated by reference to Exhibit 2.1 to the Current
Report on Form 8-K filed by Hologic, Inc. with the Securities and Exchange Commission on February 14, 2017).
|
(g)
|
|
None.
|
(h)
|
|
None.
|
8
QuickLinks
SIGNATURES
EXHIBIT INDEX
Grafico Azioni Cynosure (NASDAQ:CYNO)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Cynosure (NASDAQ:CYNO)
Storico
Da Gen 2024 a Gen 2025